Cargando…
Durvalumab for Extensive-Stage of Small-Cell Lung Cancer With Lambert-Eaton Myasthenic Syndrome
Durvalumab is an immune checkpoint inhibitor (ICI) of anti-programmed cell death protein 1 ligand antibody. ICI-combined chemotherapy has recently become a standard regimen for extensive-stage of small-cell lung cancer (ES-SCLC). SCLC is well known to be the most likely tumor associated with Lambert...
Autores principales: | Machiyama, Hirotomo, Minami, Seigo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elmer Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9990708/ https://www.ncbi.nlm.nih.gov/pubmed/36896371 http://dx.doi.org/10.14740/jmc4043 |
Ejemplares similares
-
Adenocarcinoma of Lung Presenting as Lambert-Eaton Myasthenic Syndrome
por: Bukhari, Sumera, et al.
Publicado: (2017) -
Lambert-Eaton Myasthenic Syndrome Caused by Nivolumab in a Patient with Squamous Cell Lung Cancer
por: Nakatani, Yuki, et al.
Publicado: (2018) -
Lambert-Eaton Myasthenic Syndrome in Lung Cancer
por: Wang, Yongbin, et al.
Publicado: (2022) -
Amifampridine for Lambert-Eaton myasthenic syndrome
Publicado: (2022) -
Pseudomyopathic Changes in Needle Electromyography in Lambert-Eaton Myasthenic Syndrome
por: Komatsu, Teppei, et al.
Publicado: (2013)